Want a deeper scan?
Get a guided tour of your organization’s security posture from an UpGuard team member.

Array BioPharma

This is a preliminary report on Array BioPharma’s security posture. If you want in-depth, always up-to-date reports on Array BioPharma and millions of other companies, start a free trial today. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.
Start monitoring Array BioPharma

UpGuard Security Rating

/ 950
This is a 0-950 security rating for Array BioPharma. The higher the rating, the more likely Array BioPharma has good security practices. For complete visibility of the security posture of Array BioPharma, start a free trial of UpGuard.

Company info

Array BioPharma
Array BioPharma
Last updated
Last updated
Last updated today

Security report for Array BioPharma

Array BioPharma is a U.S.-based, clinical stage, publicly traded pharmaceutical company founded in Boulder, Colorado (NASDAQ:ARRY) that is included in the NASDAQ Biotechnology Index.The company has engaged in collaborations with Pfizer and Merck to study several cancer targeting drug combinations. In July 2013 the company partnered with Loxo Oncology to develop cancer drugs, in November 2015 the company partnered with Pierre Fabre and the company also partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.In 2017 it spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.In March 2018 Array sued AstraZeneca for breach of contract, saying that AZ owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AZ in a deal for selumetinib, which Array said it had licensed to AZ in 2003.In June 2018, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) were approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.
Last updated today

Array BioPharma Data Breaches and Security News

Relevant news, breaches and security articles relating to Array BioPharma.

More security reports

Compare Array BioPharma's security performance with other companies.

Leader in Third Party & Supplier Risk Management Software

See how UpGuard shapes up against other platforms in the market.
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan rating
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.